Compare Cigna Corp (CI) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs MobilEye Global Inc — how do they compare? Cigna Corp trades at $299.91 (market cap $80.25B), while MobilEye Global Inc trades at $10.14 (market cap $8.50B). The key difference: Cigna Corp is far larger — about 9.4× MobilEye Global Inc's market cap, and Cigna Corp pays a 2.06% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals.
| CI | MBLY | |
|---|---|---|
Market Cap | $80.25B | $8.50B |
Sector | Health | Technology |
52-Week High | $311.00 | $16.27 |
52-Week Low | $244.41 | $6.56 |
Enterprise Value | $103.35B | $7.15B |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $304.50, up 3.76% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $7.79 exceeding the $7.60 estimate. Valuation metrics appear attractive with a P/E of 12.91 and P/S of 0.29. Recent news highlights strategic AI investments in pharmacy services and positive sector sentiment.
The investment case centers on undervaluation, earnings momentum, and dividend yield, though risks include regulatory challenges and moderating cash flow. With a consensus price target of $339.82 implying 11.6% upside, Wall Street maintains a bullish stance, but investors should weigh execution risks against growth initiatives.
MBLY trades at $9.75, up 2.09% today, with a bullish technical signal and strong analyst support (57.69% buy ratings). The company reported Q1 2026 EPS of $0.12, beating expectations, but faces profitability challenges with a net income margin of -203.97% for 2026. Recent news highlights its strategic shift to launch a vertically integrated U.S. robotaxi service in 2027, positioning it beyond traditional ADAS supply.
The outlook hinges on MBLY's execution of its robotaxi initiative, offering growth potential but carrying significant execution and competitive risks. While near-term fundamentals show losses, the stock's current price near the consensus target of $10.50 suggests limited upside unless profitability improves or new ventures accelerate. Investors should weigh the high-risk, high-reward profile amid volatile earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
